Literature DB >> 1827234

Prevalence of lipoprotein (a) [Lp(a)] excess in coronary artery disease.

J Genest1, J L Jenner, J R McNamara, J M Ordovas, S R Silberman, P W Wilson, E J Schaefer.   

Abstract

Lipoprotein (a) [Lp(a)] is composed of 1 low-density lipoprotein (LDL) particle, to which 1 molecule of apolipoprotein (a) is covalently linked. Elevated levels of Lp(a) have been associated with coronary artery disease (CAD) and Lp(a) has been shown to be highly heritable. Our purpose was to determine the prevalence of familial Lp(a) excess in patients with CAD. We determined plasma levels of Lp(a) in 180 patients (150 men and 30 women) with angiographically documented CAD before age 60 years, and in 459 control subjects (276 men and 183 women) clinically free of cardiovascular disease. In addition, Lp(a) levels were determined in families of 102 of the CAD probands (87 men and 15 women). No gender differences in Lp(a) levels were observed between men and women (patients or control subjects). Patients with CAD had higher Lp(a) levels than did control subjects (19 +/- 21 vs 13 +/- 15 mg/dl, p less than 0.001). The prevalence of Lp(a) excess (defined as greater than 90th percentile of controls) was 17% in patients with CAD (p less than 0.05). Lp(a) levels were not correlated with cholesterol, LDL cholesterol, high-density lipoprotein (HDL) cholesterol or apolipoproteins A-I or B. There was a weak correlation between Lp(a) and triglycerides (r = 0.166, p less than 0.05) in patients and control subjects. Stepwise discriminant analysis revealed that Lp(a) was a risk factor for the presence of CAD in men, independent of smoking, hypertension, diabetes, LDL and HDL cholesterol, or apolipoprotein A-I and B levels. Family studies revealed that Lp(a) levels are strongly genetically determined.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1827234     DOI: 10.1016/0002-9149(91)90862-f

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  10 in total

1.  Lipid profile, haemostatic variables and angiographically-defined coronary artery disease: a cross-sectional study in an Irish population.

Authors:  J Galvin; M Codd; S Leavy; D Sugrue
Journal:  Ir J Med Sci       Date:  1996 Apr-Jun       Impact factor: 1.568

2.  Serum Lp(a) lipoprotein concentration is not associated with clinical and angiographic outcome five years after coronary artery bypass graft surgery.

Authors:  J S Skinner; M Farrer; C J Albers; K Piper; H A Neil; P C Adams
Journal:  Heart       Date:  1997-08       Impact factor: 5.994

3.  Proceedings of the 10th Asian Pacific Congress of Clinical Biochemistry in conjunction with the Australasian Association of Clinical Biochemists' 42nd Annual Scientific Conference.

Authors: 
Journal:  Clin Biochem Rev       Date:  2004

4.  Prevalence of Elevated Serum Homocysteine and Serum Lipoprotein 'a' in Women.

Authors:  Alka N Sontakke; Mona A Tilak; Vaishali V Dhat; Umesh M More; Sarita A Shinde; Pradnya Phalak; Anita D Deshmukh
Journal:  J Clin Diagn Res       Date:  2014-10-20

5.  Plasma lipoprotein(a) levels and expression of the apolipoprotein(a) gene are dependent on the nucleotide polymorphisms in its 5'-flanking region.

Authors:  K Suzuki; M Kuriyama; T Saito; A Ichinose
Journal:  J Clin Invest       Date:  1997-03-15       Impact factor: 14.808

Review 6.  Familial Hypercholesterolemia and Elevated Lipoprotein(a): Cascade Testing and Other Implications for Contextual Models of Care.

Authors:  Wann Jia Loh; Dick C Chan; Pedro Mata; Gerald F Watts
Journal:  Front Genet       Date:  2022-04-27       Impact factor: 4.772

7.  Apolipoprotein(a) phenotypes, Lp(a) concentration and plasma lipid levels in relation to coronary heart disease in a Chinese population: evidence for the role of the apo(a) gene in coronary heart disease.

Authors:  C Sandholzer; E Boerwinkle; N Saha; M C Tong; G Utermann
Journal:  J Clin Invest       Date:  1992-03       Impact factor: 14.808

8.  Association of elevated lipoprotein(a) levels and coronary heart disease in NIDDM patients. Relationship with apolipoprotein(a) phenotypes.

Authors:  J Ruiz; J Thillet; T Huby; R W James; D Erlich; P Flandre; P Froguel; J Chapman; P Passa
Journal:  Diabetologia       Date:  1994-06       Impact factor: 10.122

9.  Gemfibrozil treatment in patients with elevated lipoprotein a: a pilot study.

Authors:  A G Fereshetian; M Davidson; H Haber; D M Black
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

Review 10.  Analysis of angiographic trial data in women.

Authors:  R J Havel
Journal:  Drugs       Date:  1994       Impact factor: 9.546

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.